References

Bills VL, Soothill PW Fetal blood grouping using cell free DNA - an improved service for RhD negative pregnant women. Transfus Apher Sci. 2014; 50:(2)148-53 https://doi.org/10.1016/j.transci.2014.02.005

Dan S, Wang W, Ren J, Li Y, Hu H, Xu Z, Lau TK, Xie J, Zhao W, Huang H, Xie J, Sun L, Zhang X, Wang W, Liao S, Qiang R, Cao J, Zhang Q, Zhou Y, Zhu H, Zhong M, Guo Y, Lin L, Gao Z, Yao H, Zhang H, Zhao L, Jiang F, Chen F, Jiang H, Li S, Li Y, Wang J, Wang J, Duan T, Su Y, Zhang X Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn. 2012; 32:(13)1225-32 https://doi.org/10.1002/pd.4002

Daniels G, Finning K, Martin P, Soothill P Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang. 2004; 87:(4)225-32

Ford J, Soothill P Cell-free DNA fetal blood group testing for RhD-negative pregnant women: Implications for midwifery. British Journal of Midwifery. 2016; 24:(2)96-9 https://doi.org/10.12968/bjom.2016.24.2.96

Garfield SS, Armstrong SO Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Manag Care Med. 2012; 15:(2)34-41

Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015; 45:(3)249-66 https://doi.org/10.1002/uog.14791

Hill M, Wright D, Daley R, Lewis C, McKay F, Mason S, Lench N, Howarth A, Boustred C, Lo K, Plagnol V, Spencer K, Fisher J, Kroese M, Morris S, Chitty LS Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol. BMC Pregnancy Childbirth. 2014; 14 https://doi.org/10.1186/1471-2393-14-229

Jensen KM, Bulova PD Managing the care of adults with Down’s syndrome. BMJ. 2014; 349 https://doi.org/10.1136/bmj.g5596

Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS Presence of fetal DNA in maternal plasma and serum. Lancet. 1997; 350:(9076)485-7

Nadler HL, Gerbie AB Role of amniocentesis in the intrauterine detection of genetic disorders. N Engl J Med. 1970; 282:(11)596-9

Neyt M, Hulstaert F, Gyselaers W Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open. 2014; 4:(11) https://doi.org/10.1136/bmjopen-2014-005922

London: Public Health England; 2015

Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, Tomlinson MW, Pereira L, Spitz JL, Hollemon D, Cuckle H, Musci TJ, Wapner RJ Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015; 372:(17)1589-97 https://doi.org/10.1056/NEJMoa1407349

O’Leary P, Maxwell S, Murch A, Hendrie D Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. Aust N Z J Obstet Gynaecol. 2013; 53:(5)425-33 https://doi.org/10.1111/ajo.12136

Pan Q, Sun B, Huang X, Jing X, Liu H, Jiang F, Zhou J, Lin M, Yue H, Hu P, Ning Y A prenatal case with discrepant findings between non-invasive prenatal testing and fetal genetic testings. Mol Cytogenet. 2014; 7 https://doi.org/10.1186/1755-8166-7-48

Polk RC, Gergics P, Steimle JD, Li H1, Moskowitz IP, Camper SA, Reeves RH The pattern of congenital heart defects arising from reduced Tbx5 expression is altered in a Down syndrome mouse model. BMC Dev Biol. 2015; 15 https://doi.org/10.1186/s12861-015-0080-y

van Schendel RV, Kleinveld JH, Dondorp WJ, Pajkrt E, Timmermans DR, Holtkamp KC, Karsten M, Vlietstra AL, Lachmeijer AM, Henneman L Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. Eur J Hum Genet. 2014; 22:(12)1345-50 https://doi.org/10.1038/ejhg.2014.32

van Schendel RV, Dondorp WJ, Timmermans DR, van Hugte EJ, de Boer A, Pajkrt E, Lachmeijer AM, Henneman L NIPT-based screening for Down syndrome and beyond: what do pregnant women think?. Prenat Diagn. 2015; 35:(6)598-604 https://doi.org/10.1002/pd.4579

Wu J, Morris JK The population prevalence of Down’s syndrome in England and Wales in 2011. Eur J Hum Genet. 2013; 21:(9)1016-9 https://doi.org/10.1038/ejhg.2012.294

Non-invasive prenatal testing for Down syndrome in general maternity services

02 August 2016
11 min read
Volume 24 · Issue 8

Abstract

Since its discovery in 1997, the presence of cell-free fetal DNA in the maternal bloodstream has been put to clinical use to detect variety of fetal conditions, in the antenatal period. The use of fetal DNA can offer a highly accurate screen for the presence of Down syndrome (trisomy 21). This has numerous advantages over standard first trimester combined screening for Down syndrome; for example, a reduction in miscarriages due to its non-invasive nature. This article considers a number of issues that need to be resolved before widespread implication of this type of screening into standard NHS practice.

For a woman hoping to start a family, discovering two lines on her urine pregnancy test may initiate profound excitement at a future vision of motherhood. This is followed in the subsequent weeks by a realisation that pregnancy is a potentially difficult journey, with many choices and challenges to navigate. One important decision the woman faces is whether to have first trimester screening to assess her risk of having a baby with Down syndrome. Currently, in the UK, approximately two thirds of all pregnant women opt for Down syndrome screening, with about one third declining the test for various reasons including religious, cultural or personal factors.

Down syndrome is a condition caused by an extra (and so three in total, hence ‘trisomy’) chromosome number 21 in all cells of the body. At least 95% of cases are not inherited, instead occurring due to a chance error in cell division called meiosis, which happens before the time of conception. First meiosis occurs during fetal life in females, and second meiosis occurs with formation of the ovum during each menstrual cycle. Although the risk of Down syndrome increases with advancing maternal age, more babies with Down syndrome are born to younger women (because more babies in total are born to younger women). With more than 37 000 babies born in the UK with Down syndrome in 2011 (Wu and Morris, 2013), this condition is one of the most common causes of disability. However, the clinical characteristics of Down syndrome are variable. Many people with Down syndrome have some degree of learning disability, around 50% have a congenital cardiac anomaly, and early-onset dementia and leukaemia are more likely (Polk et al, 2015). Despite these potential health risks, many people with Down syndrome attend mainstream school during childhood and are in work as adults (Jensen and Bulova, 2014).

Register now to continue reading

Thank you for visiting British Journal of Midwifery and reading some of our peer-reviewed resources for midwives. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • Unlimited access to the latest news, blogs and video content

  • Monthly email newsletter